Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Working Capital Changes: 2012-2024

Historic Other Working Capital Changes for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to -$8.9 million.

  • Akebia Therapeutics' Other Working Capital Changes fell 247.19% to -$11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 5.74%. This contributed to the annual value of -$8.9 million for FY2024, which is 24.88% up from last year.
  • Akebia Therapeutics' Other Working Capital Changes amounted to -$8.9 million in FY2024, which was up 24.88% from -$11.8 million recorded in FY2023.
  • Akebia Therapeutics' Other Working Capital Changes' 5-year high stood at $18.7 million during FY2021, with a 5-year trough of -$32.4 million in FY2020.
  • For the 3-year period, Akebia Therapeutics' Other Working Capital Changes averaged around -$5.4 million, with its median value being -$8.9 million (2024).
  • Per our database at Business Quant, Akebia Therapeutics' Other Working Capital Changes surged by 157.60% in 2021 and then tumbled by 354.38% in 2023.
  • Akebia Therapeutics' Other Working Capital Changes (Yearly) stood at -$32.4 million in 2020, then soared by 157.60% to $18.7 million in 2021, then crashed by 75.06% to $4.7 million in 2022, then plummeted by 354.38% to -$11.8 million in 2023, then rose by 24.88% to -$8.9 million in 2024.